View Full Version : Replicel begins testing of new device for precise dermal injections

08-07-2015, 11:25 AM

"“While RCI-02 was originally conceived to deliver our cellular products, we believe this device will have a profound impact on all dermal injections – particularly the cosmetic dermal injection market,” commented Dr. Rolf Hoffmann, Chief Medical Officer and visionary for the RCI-02 injector. “Dermatologists have been frustrated for years by the lack of a precise injector to deliver currently approved dermal fillers into the broad potential markets for fine wrinkles of the face, décolleté, and hands. RCI-02 is designed to address these unserved markets while also improving on current markets by enabling precise and repeatable delivery of injectable substances. RCI-02 will enable clinicians to better control injection consistency while also enabling less skilled clinicians to undertake these procedures with the desired results.”


08-08-2015, 12:56 AM
Who cares, delays delays delays for their hair loss treatment.